Biotechnology company Moderna, Inc. (NASDAQ: MRNA) has reported a net loss for the fourth quarter of 2024, compared to a profit last year.
- Total revenue for the fourth quarter was $1.0 billion, compared to $2.8 billion in the same period of FY23
- Net product sales for the quarter were $938 million, reflecting a 66% year-over-year decrease
- The company reported a net loss of $1.1 billion for the December quarter, compared to net income of $217 million in Q4 2023
- On a per-share basis, net loss was $2.91 in the fourth quarter, compared to earnings per share of $0.55 in the prior-year quarter
- Cost of sales for Q4 came in at $739 million, which included third-party royalties of $45 million, inventory write-downs of $193 million, and wind-down costs of $259 million
- Research and development expenses decreased by 20% to $1.1 billion during the three months
- Cash, cash equivalents, and investments as of December 31, 2024, were $9.5 billion, compared to $9.2 billion as of September 30, 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
DRI Earnings: Darden Restaurants’ Q2 2026 sales and profit rise YoY
Darden Restaurants, Inc. (NYSE: DRI), a leading fine dining restaurant chain, on Thursday reported an increase in sales and adjusted earnings for the second quarter of fiscal 2026. Total sales
CarMax (KMX) Q3 2026 earnings drop on lower sales; results beat estimates
Used car retailer CarMax, Inc. (NYSE: KMX) on Thursday reported a decline in earnings for the third quarter of fiscal 2026, hurt by lower sales. However, both revenues and earnings
ACN Earnings: Key quarterly highlights from Accenture’s Q1 2026 financial results
Accenture (NYSE: ACN) reported its first quarter 2026 earnings results today. Revenues of $18.7 billion increased 6% in US dollars and 5% in local currency compared to the same period a
